Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Branebrutinib and Rosuvastatin in Healthy Participants
NCT04515628Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of branebrutinib in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren's syndrome and 1 more, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration (Cmax) of rosuvastatin up to 6 days, Maximum observed plasma concentration (Cmax) of rosuvastatin when coadministered with branebrutinib at Day 13 and 4 more. Started Aug 2020; status: completed.
02
Drugs
branebrutinib
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)Sjogren's syndromeatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04515628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515628.